1.

ABSTRACT OF THE DISCLOSURE

A compound of the formula (I):

$$\begin{array}{c|c} R_2 & Z & R_3 \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\ & | \\$$

5

CJ

or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin. methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.